A father built a gene therapy for his daughter. He says an FDA request is the bottleneck

Grace Science CEO Matt Wilsey says FDA demands could kill its gene therapy for the rare and fatal NGLY1 deficiency by September without new funding or a regulatory break.

Raccontata daendpoints.news